Abcam, ab239076, Anti-FCRL4 antibody [EPR21961]

Size: 100µL / 1mL
Anti-FCRL4 antibody [EPR21961] (ab239076) is a rabbit monoclonal antibody detecting FCRL4 in IHC-P . Suitable for Human . - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR21961,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-FCRL4 antibody [EPR21961] (ab239076) is a rabbit recombinant monoclonal antibody and is validated for use in Immunohistochemistry (IHC-P) in Human samples.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Other related products
We have a range of other formats of antibody clone [EPR21961] also available for your convenience: ab239076, Carrier free -
ab239754
, Alexa Fluor® 647 -
ab320114
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FCRL4 also known as Fc receptor-like 4 is a transmembrane protein with a molecular mass of about 70 kDa. It belongs to a family of receptors similar to Fc receptors and is expressed mainly on a subset of B cells particularly on those in tonsils and mucosal tissues. This receptor is relevant because it modulates immune responses and can influence how B cells react to environmental antigens. FCRL4 expression differs from its family members suggesting a specialized function within the immune system.
Biological function summary
FCRL4 contributes to the regulation of B cell activation and differentiation. FCRL4 has been identified to form complexes with other proteins at the cellular membrane influencing signaling cascades that dampen B cell receptor signaling. This control over signaling pathways is critical for maintaining immune homeostasis and preventing overactive immune responses which can lead to autoimmune conditions. By acting through these complexes FCRL4 helps determine B cell fate during immune responses.
Pathways
FCRL4 is involved in immune regulatory pathways associated with lymphocyte activation. It intersects with the B cell receptor signaling pathway and modulates the interaction between B cell immunological synapse components. FCRL4 interacts with proteins like CD307d within these pathways serving a regulatory role in limiting excessive B cell activation. The control exerted by FCRL4 within these pathways is essential for preventing unnecessary immune activation that could be harmful.
FCRL4 holds significance in chronic infections and autoimmune disorders. Abnormal expression or malfunction of FCRL4 associates with conditions such as Sjögren's syndrome where inappropriate immune function affects secretory glands. In chronic infections FCRL4 expression identifies exhausted B cell populations that are less responsive to antigenic stimulation affecting the body's ability to fight infections. CD307d often links to FCRL4 in such cases where they may together alter disease progression by affecting B cell function in disease settings.